What is the Current Share Price of Haleos Labs Limited?
- Answer Field
-
Haleos Labs Limited share price is for NSE ₹ 1,293.50 & for BSE ₹ 1,267.00 as on Jan 09 2026 03:27 PM.
As of the latest trading session, SMS Lifesciences India Ltd share price is currently at ₹ 1293.5, which is down by ₹ -11.50 from its previous closing. Today, the stock has fluctuated between ₹ 1271.30 and ₹ 1300.10. Over the past year, SMS Lifesciences India Ltd has achieved a return of 4.26 %. In the last month alone, the return has been -5.23 %. Read More...
| Particulars | SEP 2025 (Values in Cr) |
|---|---|
| Revenue | 77.84 |
| Operating Expense | 71.24 |
| Net Profit | 4.98 |
| Net Profit Margin (%) | 6.39 |
| Earnings Per Share (EPS) | 16.46 |
| EBITDA | 11.24 |
| Effective Tax Rate (%) | 29.36 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 27.45 | 13.46 | 1.42 | 210.36 | 25.97 / 57.00 |
| BLISS GVS PHARMA LTD | 175.20 | 16.91 | 1.63 | 1853.42 | 105.05 / 195.85 |
| CIPLA LTD | 1466.15 | 21.77 | 3.59 | 118431.38 | 1310.05 / 1672.20 |
| FERMENTA BIOTECH LIMITED | 328.00 | 8.62 | 2.46 | 965.34 | 219.00 / 449.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 27.45 | 22.32 | 3.82 | 210.36 | 25.97 / 57.00 |
| AMRUTAJAN HEALTH LTD | 627.45 | 32.00 | 5.30 | 1814.00 | 548.05 / 829.00 |
| ASTRAZENECA PHARMA IND LT | 8327.35 | 90.05 | 26.05 | 20818.38 | 6501.60 / 10653.05 |
| BLISS GVS PHARMA LTD | 175.20 | 23.64 | 1.67 | 1853.42 | 105.05 / 195.85 |
Choose a Plan That Suits Your Goals and Needs
Subscription Charge : FREE
Professional Pack
Subscription Charge : ₹2,500 Yearly
Signature
SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006. The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016.
The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments. SMS Group was given the export house status in the year 1997-98.
Having three multi product facilities in operation and a research centre, the Company executed contract manufacturing and research assignment for global customer base. The Scheme of Arrangement between SMS Pharmaceuticals Limited with the Company was implemented in 2016-17. Pursuant to the Scheme, the Semi Regulated facilities i.e Unit No. I, IV and V along with premises situated at Industrial Estate, Sanathnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19.00 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units of SMS Pharmaceuticals Limited got demerged into the Company and the said Scheme of Demerger was given effect on May 17, 2017. The Company allotted 30,23,287 Equity Shares of Rs. 10 each to the shareholders of SMS Pharmaceuticals Limited on 27 June, 2017 in pursuance of Demerger Scheme.
The Company made Mahi Drugs Private Limited as a wholly owned subsidiary of the Company in 2017-18. by acquiring 9,00,000 Equity Shares effective on 17th September, 2018. Similarly, the Company diluted its 10% stake in Mahi Drugs Private Limited during the period 2021-22 and it ceased to be a wholly-owned subsidiary of the Company w.e.f. 7th February, 2022.
Company completed two regulatory inspections by the US Food and Drug Administration (USFDA). Company's Unit 1 at Kazipally, Hyderabad underwent USFDA inspection in May, 2025, resulting in a successful outcome with a Voluntary Action Indicated (VAI) status. Additionally, the Company's subsidiary, Mahi Drugs also successfully completed its USFDA inspection in February, 2025 of its manufacturing facility located in Vizag, Andhra Pradesh. Company expanded the new API production line, which is expected to become operational in the latter half of the year 2025-26.
Haleos Labs Limited share price is for NSE ₹ 1,293.50 & for BSE ₹ 1,267.00 as on Jan 09 2026 03:27 PM.
The market cap of Haleos Labs Limited for NSE ₹ 391.06 & for BSE ₹ 383.05 as on Jan 09 2026 03:27 PM.
The 52 Week High and Low of Haleos Labs Limited for NSE is ₹ 1,680.00 and ₹ 959.80 and for BSE is ₹ 1,680.00 and ₹ 956.05.
The 1 year returns on the stock has been 4.26%.
As on Jan 09 2026 03:27 PM the price-to-earnings (PE) ratio for Haleos Labs Limited share is 20.12.
As on Jan 09 2026 03:27 PM, the price-to-book (PB) ratio for Haleos Labs Limited share is 684.26.
You can trade in Haleos Labs Limited shares with Bajaj Broking by opening a demat account.
To buy Haleos Labs Limited shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Haleos Labs Limited”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found
Freedom Pack